Morning versus evening dosing of ibuprofen using conventional and time-controlled release formulations

Halsas, M.; Hietala, Jaana; Veski, Peep; Jürjenson, Heidi; Marvola, Martti

doi:10.1016/s0378-5173(99)00250-1

Cited by 38 publications

(15 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common way to prolong drug delivery is to use sustained or extended release dosage forms and aim of such strategies is to increase the availability of the active drug at the site of drug action over a prolonged period of time (Carroll et al, 1990;Shu et al, 2001). A controlled drug delivery system may result in a lower plasma concentration, but it provides a constant pharmacological availability of the drug which might reduce toxic side effects (Thielemann et al, 1996;Halsas et al, 1999;Higaki et al, 2001). This reduced side effect coupled with reduced dose frequency overcome compliance problems with patients, and eventually provides satisfactory clinical management of any disease involved (Wikstrand et al, 2003;Löbenberg et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Pharmacokinetics of Simvastatin and Its Pharmacologically Active Metabolite from Controlled-Release Tablets of Simvastatin in Rodent and Canine Animal Models

Shanmugam¹,

Ryu²,

Yoo³

et al. 2011

Biomolecules and Therapeutics

View full text Add to dashboard Cite

a These two authors equally contributed to this work.Received Oct 1, 2010 Revised Nov 1, 2010 (Duggan et al., 1989;Bradford et al., 1991;Nishio et al., 2005). It was also reported that higher incidences of adverse events are associated with higher drug concentrations of statins and the most serious adverse events associated with them are hepatotoxicity and myotoxicity (Duggan et al., 1989;Vickers et al., 1990a;Bradford et al., 1991;McClelland et al., 1991). Since, SA has the similar mechanism of action like other statins, higher peak concentrations of SA would be expected to be related with incidence of adverse events. Therefore, formulations of SA with reduced side effects and constant pharmacological activity are of interest.It was reported that lovastatin IR given as 20 mg twice daily produced a signifi cantly greater reduction in LDL cholesterol

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Pharmacokinetics of Simvastatin and Its Pharmacologically Active Metabolite from Controlled-Release Tablets of Simvastatin in Rodent and Canine Animal Models

Shanmugam¹,

Ryu²,

Yoo³

et al. 2011

Biomolecules and Therapeutics

View full text Add to dashboard Cite

show abstract

“…This pharmacodynamic principle has been widely applied as a means to improve drug therapy (107). There are numerous examples to demonstrate modulation of adverse effect of NSAIDs by SR formulations (108)(109)(110)(111)(112)(113)(114)(115). Lipid-based formulations have attracted increasing attention for improvement of bioavailability of hydrophobic drugs in comparison with solid dosage forms (116).…”

Section: Sustained and Controlled Release Formulationsmentioning

confidence: 99%

Conventional and Novel Pharmaceutical Dosage Forms on Prevention of Gastric Ulcers

Özgüney¹

2011

Peptic Ulcer Disease

View full text Add to dashboard Cite

“…9 Natural Polysaccharide such as guar gum, xanthan gum, and locast bean gum has been investigated for their use in Novel drug delivery system. 10 They remain undigested in stomach but get degraded by different anaerobic microflora in the intes-tine. 11 Gum Katira was selected as the matrix forming material because of its well-established biocompatibility, non toxic and safe material for the use in food and pharmaceutical industries.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Gum Katira as a Model Sustained Release Adjuvant in the Preparation of Etodolac Loaded Microsphere.

Ruhidas¹,

Naskar²,

Banerjee³

et al. 2016

IJPER

View full text Add to dashboard Cite

Aims:The aim of present study was to evaluate Gum Katira obtained from the plant Cochlospermum religiosum (Family Cochlospermaceae) as a matrix forming pharmaceutical excipient for a novel drug delivery system. Materials and Methods: Gum Katira was used for the drug release retarding material in microsphere formulation using Etodolac as a model drug. Etodolac was found to be compatible with the matrix material Gum Katira by conducting the various physiochemical and instrumental analysis. Result: Etodolac loaded Gum Katira microsphere (ELGKM) was compared with Etodolac loaded sodium alginate microsphere (ELSAM) and blank microsphere (without gum matrix), which subsequently revealed that the drug release rate of ELGKM was better for sustained and controlled release. Conclusion: In our experiment, it was found that the drug release mechanism best fitted in Korsmeyers Peppas model on comparing the correlation coefficient values of different mathematical models. The result of this study indicates that ELGKM (1% w/v Gum Katira) would be desired formulations in delivering the drug with controlled and sustained release pattern.

show abstract

Morning versus evening dosing of ibuprofen using conventional and time-controlled release formulations

Cited by 38 publications

References 13 publications

Evaluation of Pharmacokinetics of Simvastatin and Its Pharmacologically Active Metabolite from Controlled-Release Tablets of Simvastatin in Rodent and Canine Animal Models

Evaluation of Pharmacokinetics of Simvastatin and Its Pharmacologically Active Metabolite from Controlled-Release Tablets of Simvastatin in Rodent and Canine Animal Models

Conventional and Novel Pharmaceutical Dosage Forms on Prevention of Gastric Ulcers

Evaluation of Gum Katira as a Model Sustained Release Adjuvant in the Preparation of Etodolac Loaded Microsphere.

Contact Info

Product

Resources

About